Merck Presents Early-Stage Interim Data for MK-3475 Study for Treatment of Advanced Melanoma

Merck

announced Sunday the presentation of early interim results from a single-arm, open-label Phase IB study that has so far enrolled 132 patients with advanced (inoperable and metastatic) melanoma who have received MK-3475, Merck's investigational immune-modulating therapy. Omid Hamid, M.D., Director of the Melanoma Center at the Angeles Clinic and Research Institute, Los Angeles, presented the data during a late-breaking clinical trials session at the Society for Melanoma Research of the 9th International Congress of the Society for Melanoma Research (SMR) in Hollywood, Calif. "A key element of Merck's oncology strategy is to identify therapeutic candidates with the potential to make a meaningful difference